Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Amarin Corporation plcNASDAQ: AMRN

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2.33M fell 46.1% year over year, ahead of the -191.3% change in trailing-twelve-month stock-based compensation.

Context

  • Stock-based compensation amounted to 6.5% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -46.1% holds above the trailing-twelve-month pace of -191.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.33M+118.9% QoQ
Last fiscal yearDec 2025
$13.94M-21.3% YoY
LTMMar 2026
-$3.95M-191.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.1%——
1 year-21.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
13.94M USD
Year-over-year change
-21.3%

Stock-Based Compensation vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -191.3% is the lowest of 10, against a peer median of -5.4%.
  • Stock-based compensation amounts to 1.8% of revenue for AMRN, versus a peer median of 840.6%.
AMRN Competitors
Stock-Based Compensation for AMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$35.81M USD+19.3%—115500.0%
ALTAltimmune, Inc.LTM Mar 2026$15.44M USD+4.6%+25.7%42886.1%
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
ENGNenGene Holdings Inc.LTM Apr 2026$12.14M USD+60.2%+336.5%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$7.15M USD-15.9%+1.9%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$5.99M USD+37.2%+2.3%—
KRROKorro Bio, Inc.LTM Mar 2026$4.8M USD-10.4%+88.7%125.0%
AMRNAmarin Corporation plcLTM Mar 2026$3.95M USD-191.3%—1.8%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CLLSCellectis S.A.LTM Mar 2026$1.28M USD-60.6%—1.9%
Peer median (excluding AMRN) —-5.4%+25.7%840.6%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.73M(105.74M)(59.34M)(82.18M)(38.8M)
Depreciation & Amortization2.86M3.09M2.98M3.01M3.03M
Deferred Income Tax00000
Stock-Based Compensation00017.71M13.94M
Change in Working Capital(115.98M)(104.01M)51.27M36.17M32.28M
Accounts Receivables(8.34M)32.98M(2.33M)11.22M(3.83M)
Inventory(167.05M)(36.4M)56.34M105.44M34.96M
Accounts Payables51.51M(102.67M)(164.64K)(77.02M)14.54M
Other Working Capital7.9M2.07M(2.56M)(3.5M)(13.39M)
Other Non-Cash Items38.86M26.67M12M(5.73M)(3.71M)
Operating Cash Flow(66.53M)(179.98M)6.91M(31.03M)6.74M
Capital Expenditures2(2)(24.1K)20
Acquisitions (Net)4K0000
Purchases of Investments(290.16M)(81.58M)(215.93M)(278.78M)(200.94M)
Sales of Investments394.25M257.36M190.84M232.8M209.79M
Other Investing Activities00000
Investing Cash Flow104.09M175.18M(25.62M)(45.98M)8.85M
Debt Repayment00000
Common Stock Issued4.57M664.59K2.22M131.06K140.33K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(9.64M)(1.04M)(1.99M)(1.57M)(2.18M)
Financing Cash Flow(5.07M)(378.77K)230.89K(1.44M)(2.04M)
Effect of Forex Changes3.87K(3.2K)71.37K33.01K(31.6K)
Net Change in Cash32.49M(5.18M)(18.41M)(78.44M)13.52M
Free Cash Flow(66.53M)(179.98M)6.88M(31.02M)6.74M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.